Related Experiment Video

Updated: Aug 16, 2026

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells
10:10

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Published on: October 27, 2009

[Platelet aggregation and antiplatelet agents in acute coronary syndromes]

Jean-Philippe Collet1, Rémi Choussat, Gilles Montalescot

  • 1Institut de cardiologie, Hôpital de la Pitié-Salpêtrière, 47, boulevard de l'Hôpital, 75013 Paris, France. jean-philippe.collet@psl.ap-hop-paris.fr

Medecine Sciences : M/S
|April 7, 2004
PubMed

Insights

Antiplatelet therapy is crucial for acute coronary syndromes, preventing blood clots during treatments like PCI. Combined therapy benefits high-risk patients, but managing non-responders and interruptions is key.

Area of Science:

  • Cardiology
  • Pharmacology

Context:

  • Acute coronary syndromes (ACS) require antiplatelet agents as foundational treatment.
  • These agents prevent thrombotic complications associated with reperfusion therapies such as thrombolysis and primary percutaneous coronary intervention (PCI).
  • In non-ST elevation ACS, they avert complete thrombotic occlusion, thus preventing ST-elevation myocardial infarction.

Purpose:

  • To summarize the role and challenges of antiplatelet therapy in managing acute coronary syndromes.
  • To highlight the benefits of combined antiplatelet therapy in high-risk patient populations.
  • To address critical issues including non-response identification, dose optimization, and interruption management.

Summary:

  • Antiplatelet agents are essential in acute coronary syndromes, mitigating thrombotic risks from reperfusion therapies.
  • Combined antiplatelet therapy demonstrates superior efficacy in high-risk individuals.
  • Key challenges involve identifying non-responders, adjusting dosages, and managing temporary interruptions in stable coronary artery disease.

Impact:

  • Optimizing antiplatelet strategies can improve outcomes for patients with acute coronary syndromes.
  • Addressing non-response and treatment interruptions is vital for maximizing therapeutic benefits.
  • This research informs clinical practice regarding personalized antiplatelet therapy selection and management.

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...